Abstract
There is an increasing need for successfully managing the rapidly progressing posterior eye diseases such as age-related macular degeneration, diabetic retinopathy and glaucoma. Therefore the challenges of drug delivery to the posterior eye are compounded by growing number of new therapeutic entities and the need for chronic therapy. Currently, the intravitreal route is widely used to deliver drugs, but frequent administration of drugs via this route can lead to retinal detachment, endophthalmitis and increased intraocular pressure. Controlled delivery systems, such as implants and nanoparticles have been developed to overcome these issues, but they are not devoid of adverse effects. Periocular route is a promising alternative owing to the large surface area and the relatively high permeability of the sclera. Yet, the blood retinal barriers and efflux transporters hamper the transport of therapeutic entities to the retina. As such the efficient delivery of drugs to the posterior eye remains a major challenge facing the pharmaceutical scientist. This review discusses the barriers to posterior eye drug delivery and current strategies used to overcome these barriers.
Keywords: Implants, Intravitreal route, Iontophoresis, Microneedles, Posterior eye drug delivery, Transscleral route, Drug Delivery Systems, transscleral routes, transdermal delivery
Drug Delivery Letters
Title: Drug Delivery to the Posterior Segment of the Eye: Challenges and Opportunities
Volume: 1 Issue: 1
Author(s): T. R. Thrimawithana, S. Young, C. R. Bunt, C. R. Green and R. G. Alany
Affiliation:
Keywords: Implants, Intravitreal route, Iontophoresis, Microneedles, Posterior eye drug delivery, Transscleral route, Drug Delivery Systems, transscleral routes, transdermal delivery
Abstract: There is an increasing need for successfully managing the rapidly progressing posterior eye diseases such as age-related macular degeneration, diabetic retinopathy and glaucoma. Therefore the challenges of drug delivery to the posterior eye are compounded by growing number of new therapeutic entities and the need for chronic therapy. Currently, the intravitreal route is widely used to deliver drugs, but frequent administration of drugs via this route can lead to retinal detachment, endophthalmitis and increased intraocular pressure. Controlled delivery systems, such as implants and nanoparticles have been developed to overcome these issues, but they are not devoid of adverse effects. Periocular route is a promising alternative owing to the large surface area and the relatively high permeability of the sclera. Yet, the blood retinal barriers and efflux transporters hamper the transport of therapeutic entities to the retina. As such the efficient delivery of drugs to the posterior eye remains a major challenge facing the pharmaceutical scientist. This review discusses the barriers to posterior eye drug delivery and current strategies used to overcome these barriers.
Export Options
About this article
Cite this article as:
R. Thrimawithana T., Young S., R. Bunt C., R. Green C. and G. Alany R., Drug Delivery to the Posterior Segment of the Eye: Challenges and Opportunities, Drug Delivery Letters 2011; 1 (1) . https://dx.doi.org/10.2174/2210304x11101010040
DOI https://dx.doi.org/10.2174/2210304x11101010040 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenomics of Open-Angle Glaucoma
Current Pharmacogenomics and Personalized Medicine Intravitreal Bevacizumab for Diabetic Retinopathy
Current Diabetes Reviews PEDF in Angiogenic Eye Diseases
Current Molecular Medicine Recent Development in Applications of Important Biopolymer Chitosan in Biomedicine, Pharmaceuticals and Personal Care Products
Current Tissue Engineering (Discontinued) Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Involvement of Orbital Structures in Rheumatic Disease
Current Rheumatology Reviews Pharmacological Benefits of Active Components of Natural Products Against Traumatic Brain Injury - A Review
Current Pharmacogenomics and Personalized Medicine Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology Disintegrins
Current Drug Targets - Cardiovascular & Hematological Disorders Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design Erythropoietin in Stroke Therapy: Friend or Foe
Current Medicinal Chemistry Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase
Current Pharmaceutical Design The Medical and Medico-legal Complications of Bulimia Nervosa : Treatments and Complications
Current Women`s Health Reviews Use of Anti-VEGF Drugs in Retinal Vein Occlusions
Current Drug Targets Nucleoside Transporter Proteins
Current Vascular Pharmacology From Proteins to Nucleic Acid-Based Drugs: The Role of Biotech in Anti-VEGF Therapy
Anti-Cancer Agents in Medicinal Chemistry Anti-Angiogenic Treatment for Exudative Age-Related Macular Degeneration: New Strategies are Underway
Current Angiogenesis (Discontinued) Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema
Current Drug Safety